Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of ...

The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.

Even six years after brain tumor surgery, invisible symptoms like brain fog and memory loss shape how I live, cope, and find ...

A system that alerts doctors when high-risk cancer patients are admitted helped reduce hospital readmissions and shorten ...

Samantha Bianzon explained what biology-guided radiation therapy for cancer is, as well as highlighted how it may differ from ...

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

Living with Lynch syndrome, nature’s quiet resilience teaches me to accept change, find calm, and stay rooted through life’s ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

Disparities in cancer care can often lead to delays, disruptions, and barriers to timely treatment, leading to an unmet need ...

Q-TWiST may help patients with advanced kidney cancer and their doctors weigh treatment options by focusing on quality of ...

Treatment with Zusduri had a median duration of response of 3.5 years and event-free survival of two years in low-grade ...

Researchers are building on the success of CAR T therapy in blood cancers to explore its use in clear cell renal cell ...